Multiple Sclerosis - My Natural Reversing Trip!

 https://multiplesclerosisnewstoday.com/news-posts/2024/03/06/actrims-2024-two-treatments-aid-remyelination-ms-nearing-clinical-trials/   Convelo Therapeutics is developing two experimental oral treatments to promote myelin repair in multiple sclerosis (MS) and both have shown promise in preclinical models. The company is in the final stages of safety studies in large animals. Once those studies are done, it plans to start studies that support regulatory applications to move the treatments toward clinical trials, according to Brad Lang, Convelo’s vice president of research.   https://mtrb.org/the-future-of-stem-cell-therapy-for-ms-multiple-sclerosis-treatment/ Understanding Stem Cell Therapy for MS Types of Stem Cells Used in MS Treatment Recent Advances in Stem Cell Therapy for MS The Potential of Stem Cell Therapy in MS Challenges and Future Directions Conclusion  

  https://neurosciencenews.com/myelin-movement-ms-neuropharmacology-37518/ Summary: A new drug, PIPE-307, shows promise in reversing multiple sclerosis (MS) damage by promoting myelin regeneration around nerve cells, potentially restoring movement and function. Developed by researchers, this innovative therapy targets a specific receptor, M1R, and has already demonstrated success in animal models. PIPE-307 is currently in Phase II clinical trials, offering hope for a groundbreaking treatment that could stop and even heal the damage caused by MS. This novel approach could transform the future of MS therapy by addressing both symptoms and underlying damage.   New treatment may stop and potentially reverse some nerve damage in MS https://www.medicalnewstoday.com/articles/new-treatment-may-stop-potentially-reverse-nerve-damage-ms#Early-progress-could-give-hope-to-MS-patients  The newly developed drug — PIPE-307 — blocks the M1R receptor, allowing the OPCs to differen...